- Home
- COP vs VRTX Comparison
COP vs VRTX Comparison
Compare COP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COP
- VRTX
- Stock Information
- Founded
- COP 1917
- VRTX 1989
- Country
- COP United States
- VRTX United States
- Employees
- COP N/A
- VRTX N/A
- Industry
- COP Integrated oil Companies
- VRTX EDP Services
- Sector
- COP Energy
- VRTX Technology
- Exchange
- COP Nasdaq
- VRTX Nasdaq
- Market Cap
- COP 119.9B
- VRTX 96.6B
- IPO Year
- COP N/A
- VRTX 1991
- Fundamental
- Price
- COP $94.67
- VRTX $410.82
- Analyst Decision
- COP Buy
- VRTX Buy
- Analyst Count
- COP 16
- VRTX 25
- Target Price
- COP $116.88
- VRTX $493.64
- AVG Volume (30 Days)
- COP 6.4M
- VRTX 1.7M
- Earning Date
- COP 11-06-2025
- VRTX 11-03-2025
- Dividend Yield
- COP 3.28%
- VRTX N/A
- EPS Growth
- COP N/A
- VRTX N/A
- EPS
- COP 7.47
- VRTX 14.07
- Revenue
- COP $59,386,000,000.00
- VRTX $11,418,800,000.00
- Revenue This Year
- COP $8.96
- VRTX $10.90
- Revenue Next Year
- COP N/A
- VRTX $9.57
- P/E Ratio
- COP $12.76
- VRTX $29.16
- Revenue Growth
- COP 2.25
- VRTX 10.46
- 52 Week Low
- COP $79.88
- VRTX $362.50
- 52 Week High
- COP $116.08
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- COP 50.20
- VRTX 61.10
- Support Level
- COP $93.13
- VRTX $400.74
- Resistance Level
- COP $95.42
- VRTX $411.91
- Average True Range (ATR)
- COP 2.08
- VRTX 8.84
- MACD
- COP 0.01
- VRTX 3.92
- Stochastic Oscillator
- COP 41.89
- VRTX 97.78
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. In 2024, it produced 2.0 million barrels per day of oil and natural gas liquids and 3.4 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2024 were 7.8 billion barrels of oil equivalent.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.